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ABSTRACT 
Unraveling the mechanisms underlying Takotsubo (TTS) leads to question the 
current inclusion of the condition within the spectrum of cardiomyopathies. Indeed, 
the clinical presentation and pathophysiology of TTS clearly differ from 
cardiomyopathies, i.e. diseases of heart muscle unexplained by abnormal loading 
conditions or coronary artery disease, which cannot recover spontaneously and may 
cause sudden death often in minimally symptomatic individuals or result in a gradual 
deterioration in ventricular function and end-stage heart failure. Furthermore, the 
term ’cardiomyopathy‘  can no longer be applied when functional or morphologic 
abnormalities of the coronary arteries leading to acute myocardial ischemia are 
deemed responsible for left ventricular (LV) systolic dysfunction. 
After 27 years of investigation, time has come to recognize that patients with TTS do 
suffer from severe myocardial ischemia and fulfill all criteria of acute coronary 
syndromes, i.e. acute chest pain, typical electrocardiographic changes, cardiac 
troponin rise, as well as LV wall motion abnormalities. Accordingly, we propose that 
TTS should be labeled as an acute ’syndrome‘ to be included more appropriately 
within the spectrum of ischemic heart disease. With regard to the term ’stress‘, it may 
imply that the catecholamine surge is essential to produce the typical transient 
myocardial injury. Thus, the terminology ’Takotsubo (stress) syndrome‘ would more 
accurately reflect recent advances in the pathophysiology. 
 
Keywords 
Takotsubo; apical ballooning syndrome; catecholamine; coronary circulation, 
myocardial ischemia; stunning. 
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ABBREVIATIONS AND ACRONYMS 
 
AHA = American Heart Association 
ESC = European Society of Cardiology 
ISFC = International Society and Federation of Cardiology 
LV = left ventricle 
TTS = Takotsubo Syndrome 
WHO = World Health Organization 
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Definition and classification of cardiomyopathies 
 
Exactly 60 years ago, the term ‘cardiomyopathy’ was first used to define myocardial 
disease not caused by coronary artery disease, anda few years later a systematic 
approach to the classification of cardiomyopathies according to clinical presentation 
was proposed.1In 1980, the World Health Organization/International Society and 
Federation of Cardiology (WHO/ISFC) Task Force published a report on the 
‘definition and classification of cardiomyopathies’ designed to promote the use of a 
common rational approach to nomenclature (1). Cardiomyopathies were defined as 
‘heart muscle diseases of unknown causes’ to distinguish them from those secondary 
to systemic/cardiac causes such as hypertension, ischemic heart disease and 
valvular disease.1 Since then, continuous progress has been made with regard to the 
understanding of etiology, pathogenesis, diagnosis and therapy of heart muscle 
diseases and new forms of cardiomyopathy such as arrhythmogenic right ventricular 
and restrictive cardiomyopathies have been identified (2). 
In 1995, a WHO/IFSC Task Force attempted to account for this rapid evolution of 
knowledge by proposing a new consensus classification in which cardiomyopathies 
were defined as ’disease of the myocardium associated with cardiac dysfunction‘ and 
were defined according to anatomy and physiology (3).  After a further 10 years, an 
expert panel under the auspices of the American Heart Association (AHA) proposed 
a revision of the 1995 classification in which cardiomyopathies were defined as ‘a 
heterogeneous group of diseases of the myocardium associated with mechanical 
and/or electrical dysfunction … due to a variety of causes that frequently are genetic’ 
(4). Cardiomyopathies were considered as either primary or secondary, with the 
former being those solely or predominantly confined to heart muscle that can be 
further classified as genetic, mixed or acquired, and the latter showing pathological 
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myocardial involvement as part of a systemic condition.  
In 2008, the European Society of Cardiology (ESC) working group on myocardial and 
pericardial diseases proposed an update to the WHO/ISFC classification in which 
cardiomyopathy was defined as ‘a myocardial disorder in which the heart muscle is 
structurally and functionally abnormal in the absence of coronary artery disease, 
hypertension, valvular disease and congenital heart disease sufficient to explain the 
observed myocardial abnormality’ (5). These exclusions were justified on the premise 
that the diagnosis and treatment of these common disorders generally involve clinical 
issues quite different from those encountered in most cardiomyopathies, as originally 
proposed in 1995 (3). 
The most recent innovation in disease nosology is the MOGE(S) classification (6), 
which describes disease using five categories: morpho-functional phenotype (M), 
organ(s) involvement (O), genetic inheritance pattern (G), etiological annotation (E) 
including genetic defect or underlying disease/substrate, and the functional status 
(S). The system is based on nomenclatures used in other settings (particularly 
cancer) and is designed to be sufficiently flexible to be able to take into account new 
or emerging information about disease and phenotype (6). 
 
Takotsubo labeled as a new cardiomyopathy 
It is been 27 years since Sato et al. described an unusual appearance of the left 
ventricle (LV), which resembled the ‘takotsubo’, a Japanese fisherman’s pot with a 
round bottom and narrow neck used for trapping octopuses (7). The term Takotsubo 
was subsequently used to describe a clinical condition in which patients present with 
an abrupt onset of angina-like chest pain and diffuse T-wave inversion, sometimes 
preceded by ST-segment elevationand cardiac enzyme release (8,9). Initially, the 
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presentation is indistinguishable from an acute coronary syndrome, but it can be 
subsequently differentiated by the demonstration of angiographically normal 
epicardial coronary arteries and involvement of myocardium that extends beyond a 
single epicardial coronary vessel territory that recovers in few days or weeks (8,9). 
As is usual when a new disease is described, this condition acquired a remarkable 
multiplicity of individual descriptive names, including ‘apical ballooning’, ‘broken heart 
syndrome’ and  ‘ampulla cardiomyopathy’, but Takotsubo and stress cardiomyopathy 
have become the preferred terms and, in the 1995 WHO/IFSC Task Force 
classification, were included for the first time as an acquired primary form of 
cardiomyopathy (3). 
 
Is the Takotsubo phenomenon a cardiomyopathy? 
Using current ESC and AHA definitions for cardiomyopathy, TTS qualifies as a 
cardiomyopathy, but it differs in several important respects from other forms of heart 
muscle disease. Although there is no doubt  that mechanisms of TTS still need to be 
fully elucidated, available data indicate that, at variance with all other 
cardiomyopathies, TTS  does not have any objective marker of a primary myocardial 
injury and is almost always associated with restitutio ad integrum (10). TTS is often 
precipitated by physical or emotional stress and available evidence clearly shows 
that catecholamines are a key part of its pathogenesis (10). However, the histological 
appearances of TTS are quite different from those seen in other states such as 
phaeochromocytoma in which cathecolamine toxicity is implicated. In these 
scenarios, there is contraction band necrosis – a unique form of myocyte injury 
characterized by hypercontracted sarcomeres, dense eosinophilic transverse bands, 
and an interstitial mononuclear inflammatory response - that is distinct from the 
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polymorphonuclear inflammation seen with infarction (11).  In contrast, in TTS, serial 
myocardial biopsies during the phase of severely impaired LV function and after 
functional recovery show cell swelling and widening of the interstitial space followed 
by normalization of the myocardium with normal size of myocytes, a few small 
vacuoles, and a regular interstitium (12). 
The lack of irreversible morphologic changes in TTS is further demonstrated by data 
from cardiac magnetic resonance (CMR). The technique can distinguish TTS from a 
catecholamine-mediated myocarditis, which commonly occurs in pheochromocytoma 
(13).  The histologic footprint of pheochromocytoma, that include degenerative 
changes in muscle fibers, foci of necrosis, acute inflammation, chronic interstitial 
inflammatory exudation, and replacement-type fibrosis, may be observed on CMR as 
myocardial necrosis and diffuse fibrosis that may be associated with long-term LV 
functional changes (13). A completely different pattern is observed in TTS patients. 
CMR studies have shown that the acute phase of the disease is characterized only 
by intense myocardial edema, with a lack of macroscopic fibrosis. Testa and Feola 
were able to obtain serial CMR data in some patients with TTS and found no 
evidence of delayed enhancement after gadolinium injection either in the acute 
phase or at 3 months follow up, suggesting that the damage in the dysfunctional 
areas was transient and did not include significant necrosis (14). 
None of the existing cardiomyopathy classifications really consider this notion of 
reversibility. In genetic disease, the underlying defect is permanent, and while it could 
be argued that dysfunction can be ‘reversed’ with therapy (as in dilated 
cardiomyopathy, for example), the intrinsic myocardial defect remains and is never 
cured.  Heart muscle disease caused by myocarditis can be a reversible phenotype, 
but is more often associated with some permanent damage to the myocardium and 
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(depending on the cause) be a chronic disease with periods of relapse and 
remission.  
In the 2008 ESC classification, TTS was included as a unique-single category 
defined as an ‘unclassified’ and ‘non-familial’ cardiomyopathy despite the lack of a 
distinct chronic phenotype, the absence of a genetic origin, and no clear 
manifestation of structural abnormalities (5). Similarly, it is quite questionable whether 
Takotsubo can be accommodated in the MOGE(S) classification as the five attributes 
of a cardiomyopathy cannot be applied after the acute phase (6). In short, the 
inclusion of Takotsubo within the spectrum of cardiomyopathies is questionable (15). 
 
Myocardial ischemia in Takotsubo 
New information has shed additional light on the pathogenesis of TTS supporting the 
concept that the condition is caused by acute myocardial ischemia (10). The crucial 
role of myocardial ischemia in TTS has emerged thanks to the evidence that most 
cases of TTS occur in patients with risk factors for coronary disease and/or co-
morbidities, including neurologic, psychiatric, pulmonary, kidney, liver and connective 
tissue disease (16), that are associated with endothelial dysfunction and might 
therefore constitute a previously unrecognized predisposing factor for TTS (17).  
Indeed, endothelial dysfunction could explain the propensity to epicardial and/or 
microvascular coronary artery spasm of the disease (18).  This pathologic state of the 
endothelium characterized by an imbalance between vasoconstricting and 
vasodilating factors, may represent an important link between stress and myocardial 
dysfunction in TTS (10).  Since the first description of TTS, coronary vasospasm has 
been suggested as a plausible causative factor. In their original report, Sato et al. (7) 
reported epicardial coronary artery spasm in 8 of 35 patients (23%) and diffuse 
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coronary vasoconstriction in 19 (54%).  Similarly, Angelini et al. confirmed the 
development of coronary spasm in TTS patients who underwent acetylcholine testing 
(19). 
In addition to abnormalities of the epicardial arteries, coronary microvascular 
dysfunction might play a pathogenetic role in TTS (Figure 1)(20).  Small coronary 
arteries and arterioles receive autonomic innervation and are the principal 
determinants of coronary vascular resistance. In normal subjects the overall 
response to sympathetic activation is vasodilatation mainly through activation of 
coronary 2-adrenoceptors. By contrast, in patients with endothelial dysfunction 
Increased cardiac sympathetic activity can induce -adrenoceptor mediated coronary 
microvascular constriction powerful enough to provoke myocardial ischemia (21). 
Abnormal coronary microvascular responses have been documented in TTS using 
invasive and non-invasive diagnostic tools (22).  At time of urgent coronary 
angiography, there is evidence of reduced Thrombolysis in Myocardial Infarction 
frame count (23). Using myocardial contrast echocardiography, clear perfusion 
defects can be observed in the LV segments showing reduced contractility. These 
perfusion defects usually improve transiently with intracoronary adenosine and 
recover permanently at 1-month of follow-up (24). Single photon emission computed 
tomography perfusion studies have shown a decrease in tracer uptake during the 
acute phase of TTS and a return to normal at follow-up, further suggesting a role for 
coronary microvascular dysfunction as a trigger of myocardial ischemia in this 
condition (25). In summary, there is now agreement that the increased concentration 
of catecholamine occurring in the acute phase of TTS induces direct myocardial 
injury and coronary vasoconstriction, mostly at the microvascular level, together with 
an increased cardiac workload that contribute to an acute situation of ‘supply-
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demand mismatch’ followed by post-ischemic stunning. The clinical counterpart is the 
typical, reversible LV ballooning followed by complete functional recovery in most 
cases (Figure 2)(10). 
 
Takotsubo, a novel form of ischemic heart disease 
Unraveling the mechanisms underlying TTS leads to question the current inclusion of 
the condition within the spectrum of cardiomyopathies (17). Indeed, the clinical 
presentation and pathophysiology of TTS clearly differ from cardiomyopathies, i.e. 
diseases of heart muscle unexplained by abnormal loading conditions or coronary 
artery disease, which cannot recover spontaneously and may cause sudden death 
often in minimally symptomatic individuals or result in a gradual deterioration in 
ventricular function and end-stage heart failure. Furthermore, the term 
’cardiomyopathy‘  can no longer be applied when functional or morphologic 
abnormalities of the coronary arteries leading to acute myocardial ischemia are 
deemed responsible for LV systolic dysfunction. 
After 27 years of investigation, time has come to recognize that patients with TTS do 
suffer from severe myocardial ischemia and fulfill all criteria of acute coronary 
syndromes, i.e. acute chest pain, typical electrocardiographic changes, cardiac 
troponin rise, as well as LV wall motion abnormalities (Central Illustration). 
Accordingly, we propose that TTS should be labeled as an acute ’syndrome‘ to be 
included more appropriately within the spectrum of ischemic heart disease (17). With 
regard to the term ’stress‘, it may imply that the catecholamine surge is essential to 
produce the typical transient myocardial injury. Thus, the terminology ’Takotsubo 
(stress) syndrome‘ would more accurately reflect recent advances in the 
pathophysiology (10). 
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Figure 1    Mechanism of Myocardial Ischemia 
Coronary microvascular dysfunction has recently emerged as a potential mechanism 
of myocardial ischemia. As in the case of the other two pathogenetic mechanisms, 
atherosclerotic disease and/or epicardial coronary vasospasm, coronary 
microvascular dysfunction (alone or in combination with the two) can lead to transient 
myocardial ischemia as in patients with coronary artery disease or cardiomyopathy or 
to severe acute ischemia as observed in Takotsubo syndrome.  
CAD, coronary artery disease; CFR, coronary flow reserve; CMP, cardiomyopathy. 
The figure is from Crea F et al. and with permission (20). 
 
Figure 2   Key Pathogenetic Aspects in Takotsubo Syndrome 
The picture depicts the interplay among triggers, pathogenetic factors, mechanisms 
of cardiac injury, and clinical consequences. Current evidences indicate that in the 
acute phase of TTS there is an increased concentration of catecholamines that might 
induce direct myocardial injury and coronary spasm, mostly at the microvascular 
level, together with an increased cardiac workload that contribute to an acute 
situation of ‘supply-demand mismatch” followed by post-ischemic stunning. 
ANS, autonomic nervous system; CNS, central nervous system; LV, left ventricular; 
MVO2, myocardial oxygen consumption.  
 
The figure is from Pelliccia F et al. and with permission (10). 
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Highlights 
 
 “Takotsubo is not a Cardiomyopathy” 
 
 The current inclusion of Takotsubo syndrome within the spectrum of 
cardiomyopathies should be questioned 
 The term ’cardiomyopathy‘ can no longer be applied when functional or morphologic 
coronary abnormalities occur 
 Clinical presentation and pathophysiology of Takotsubo syndrome clearly differ from 
cardiomyopathies  
 Patients with Takotsubo syndrome do suffer from severe myocardial ischemia and 
fulfill all criteria of acute coronary syndromes 
 Takotsubo syndrome should be included more appropriately within the spectrum of 
ischemic heart disease 
